Bastelica, Paul
Renard, Jean Paul
Aptel, Florent
Labbé, Antoine
Schweitzer, Cédric
Poli, Muriel
Rousseau, Antoine
Lamirel, Cédric
Baudouin, Christophe
Article History
Received: 20 February 2024
Accepted: 12 March 2024
First Online: 8 April 2024
Declarations
:
: Paul Bastelica received speaker honoraria and/or travel grants from Horus Pharma and Théa, outside the scope of this work. Jean Paul Renard is a consultant for Bausch & Lomb, Horus Pharma, Santen and Théa. Florent Aptel is a consultant for Alcon, Bausch & Lomb, Densmore, Elios, Eyetechcare, Glaukos, Horus Pharma and Théa. Antoine Labbé is a consultant for Alcon, AbbVie, Bausch & Lomb, Elios, Horus Pharma, Glaukos, Théa and Santen. Cédric Schweitzer is a consultant for Alcon, Bausch & Lomb, Glaukos, Horus Pharma, Nicox, Santen and Théa. Muriel Poli is a consultant for Bausch & Lomb, Horus Pharma and Théa. Antoine Rousseau is a consultant for AbbVie, Glaukos, Horus Pharma and Théa; and received speaker honoraria and/or travel grants from AbbVie, Alnylam pharmaceuticals, Bausch & Lomb, Santen and Théa, outside the scope of this work. Cédric Lamirel is a consultant for Biogen, Gensight and Horus Pharma; and received travel grants from Horus Pharma and Théa, outside the scope of this work. Christophe Baudouin is a consultant for Alcon, Glaukos, Horus Pharma, Oculis, Santen and Théa.
: The study was made in accordance with the principles of the Declaration of Helsinki. All patients gave their free and informed written consent after an explanation of the study design and purpose by their treating physician. Patients’ confidentiality was ensured. The research was approved by the Rothschild Foundation Hospital review board—IRB00012801- under the study number CE_20230124_12_CBN.